A new study validating OptiScan’s endomicroscopic technology has this week been published in Nature Biomedical Engineering, one of the world’s leading medical research journals.
The study, led by Memorial Sloan Kettering Cancer Centre, found that OptiScan’s ViewnVivo “has the potential to be used for intraoperative, PARPi-FL-based in vivo imaging without tissue excision”.
OptiScan’s technology enables real-time, 3D, in vivo imaging of human tissue at the cellular level. It provides instant virtual biopsies for cancer screening, diagnoses, and treatment.
For more on the study, click here.
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.